SCHEMBL16079026

SCHEMBL16079026

CCCCOC1CC(NC(=O)Nc2ncn(Cc3ccc(Cl)cc3)c2C(=O)OCC)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ EPHX2 P34913 2/20 0.38
▸ MAPT P10636 3/20 0.36
▸ HTT P42858 2/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ RIN1 Q13671 1/20 0.36
▸ RECQL P46063 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ P2RX3 P56373 3/20 0.34
▸ GAA P10253 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ PDE4B Q07343 1/20 0.33
▸ PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16028382 0.88 MAPT (0.40) SMN1; SMN2EPHX2MAPTRECQLMAPK10
SCHEMBL16076192 0.77 SCD (0.40) EPHX2MAPTKDM4EGAAMEN1
SCHEMBL21499660 0.73 MAPT (0.39) SMN1; SMN2MAPTRECQLMAPK10KDM4E
SCHEMBL16028248 0.68 SMN1; SMN2 (0.54) SMN1; SMN2MAPTHTTRECQLMAPK10
SCHEMBL12429215 0.67 TP53 (0.49) SMN1; SMN2MAPTHTTRECQLMAPK10
SCHEMBL2700156 0.67 SMN1; SMN2 (0.50) SMN1; SMN2MAPTRECQLMAPK10KDM4E
SCHEMBL12429208 0.66 TP53 (0.47) SMN1; SMN2EPHX2MAPTRECQLMAPK10
SCHEMBL18833857 0.66 KDM4E (0.38) EPHX2MAPTHTTABL1RIN1
SCHEMBL16079029 0.64 CNOT7 (0.43) ALDH1A1LMNA
SCHEMBL12803808 0.64 SMN1; SMN2 (0.50) SMN1; SMN2MAPTHTTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-10-26 — — US disclosed
US-20160237089-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. 2016-08-18 — — US disclosed
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885EPHX2 1269/4885MAPT 2951/4885
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885EPHX2 1269/4885MAPT 2951/4885
US-20160237089-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885EPHX2 1269/4885MAPT 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback